Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
VA Tech Wabag Limited - Trading Plan under SEBI (PIT) Reg., 2015

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

0
VA Tech Wabag Limited - Shareholders meeting

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

0
Va Tech WABAG board gives nod to raise funds

2018-07-09 moneycontrol
The Board of water treatment player VA Tech WABAG Ltd on Monday approved the proposal to raise funds through non-convertible debentures of up to Rs 300 crore.
VTUWY 533269 WABAG

0
VA Tech Wabag Limited - Outcome of Board Meeting

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

0
US-China trade war tensions to take centre stage in coming week; These 3 stocks to be in focus

2018-07-08 moneycontrol
The upcoming week will be important for the market as developments around imposition of US-China tariffs are likely to stay in focus through the week.
BAJAJ-AUTO KESORAMIND SHALPAINTS 532418 KTKBANK 532218 532977 SOUTHBANK 532187 INOXWIND HEROMOTOCO 500231 502937 INDUSINDBK VTUWY 533269 500182 532652 532210 ONP UMANGDAIR CUB HRTQY 539083 509874 KRIDF WABAG ANDHRABANK

0
Va Tech Wabag rises 3%, to consider fund raising on July 9

2018-07-05 moneycontrol
Shares of Va Tech Wabag gained more 3 percent in the opening trade on Thursday as company to consider fund raising on July 9.
VTUWY 533269 WABAG

22
Market Update: Nifty pharma sprints ahead as Sun Pharma zooms 8%; Bajaj Finance hits new 52-week high

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday afternoon but managed to regained some lost ground with the Nifty trading lower by 11 points at 10,757 and the Sensex shed 41 points at 35,422.
500408 IOB 500325 AUROPHARMA FSL RELIANCE 532418 TCHQY 532755 511389 VIDEOIND TTNQY CADILAHC 532388 532321 500470 532540 532461 RIGD BJJQY 500570 TATAMOTORS RLNIY 500034 UBNC 532809 524804 VTUWY CDLYY 539207 TECHM 533269 BAJFINANCE TTST PNJZY TATASTEEL TATLY SINTEX ARBQY 502742 TATAELXSI TCS PNB MANPASAND WABAG ANDHRABANK TTM

16
17
Market Update: Nifty pharma outperforms, jumps 2.5% led by Sun Pharma; HPCL, BPCL shed 2%

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday morning with the Nifty trading lower by 31 points at 10,736 and the Sensex shed 87 points at 35,375.
500408 500325 AUROPHARMA FSL RELIANCE TCHQY 532755 511389 VIDEOIND TTNQY 500470 532540 RIGD AJANTPHARM 500570 TATAMOTORS RLNIY 532809 524804 532505 VTUWY 539207 TECHM 533269 532331 TTST TATASTEEL TATLY ARBQY TATAELXSI TCS UCOBANK MANPASAND WABAG TTM

2
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 00B63WX27